Company: REVB
Filing Date: 2025-03-06
Form Type: 10-K
Source: 0000950170-25-034584
Chunk: 192

Company: REVELATION BIOSCIENCES, INC.
Filing Date: 2025-03-06
Form: 10-K
Item: Item 1B
Chunk 192
---
 work related to the Company:

    Non-equity incentive plan compensation ($)

    Name and Position
     
    Year
     
    Salary ($)
     
    Bonus ($)(1)
     
    Stock-based awards ($)
     
    Option-based awards ($)
     
    Annual incentive plans
     
    Long term incentive plans
     
    All other compensation ($)(2)
     
    Total compensation ($)

    James Rolke
     
    2024
     
    561,000
     
    237,500
     
    —
     
    —
     
    —
     
    —
     
    14,726
     
    813,226

    CEO
     
    2023
     
    475,000
     
    160,000
     
    —
     
    —
     
    —
     
    —
     
    14,250
     
    649,250

    Chester S. Zygmont, III
     
    2024
     
    405,000
     
    142,579
     
    —
     
    —
     
    —
     
    —
     
    16,427
     
    564,006

    CFO
     
    2023
     
    356,448
     
    112,000
     
    —
     
    —
     
    —
     
    —
     
    10,693
     
    479,141

____________

(1)The amounts reflected in the column entitled “Bonus” reflect the cash amount of bonus earned by each of the officers in consideration for their fiscal 2024 and 2023 performance, respectively, but paid to such officers during fiscal 2025 and 2024, respectively.

(2)Unless otherwise indicated, the amounts reported in this column represent the Company’s matching contribution to the named executive officers Simple IRA plan account paid by the Company.

 76

OUTSTANDING EQUITY AWARDS AT FISCAL YEAR END

Outstanding Equity Awards

The following table provides information regarding the 2021 Equity Incentive Plan awards and the 2020 Equity Incentive Plan awards for each named executive officer outstanding as of December 31, 2024:

    Option-based Awards

    Stock-based Awards

    Name
     
    Date of Grant(1)
     
    Number of securities underlying unexercised options (#)
     
    Option exercise price ($)
     
    Option expiration date
     
    Value of unexercised in-the-money options at December 31, 2024 ($)
     
    Number of shares or units of shares